Related Experiment Video
Updated: Jun 25, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Red Blood Cell Transfusion Characteristics and Morbidity or Mortality in Very-Low-Birth-Weight Infants
Jeanne E Hendrickson1,2, Rebecca J Birch3, Elizabeth A K Rowley3
1Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia.
This study found that pretransfusion hemoglobin levels and anticoagulant preservative solutions impact outcomes in very-low-birth-weight (VLBW) infants receiving red blood cell (RBC) transfusions. Other modifiable factors showed no significant associations with composite morbidities or mortality.
Area of Science:
- Neonatal Medicine
- Hematology
- Pediatric Transfusion Medicine
Background:
- Few studies have explored modifiable aspects of red blood cell (RBC) transfusions and their association with recipient outcomes in very-low-birth-weight (VLBW) infants.
- Understanding these associations is crucial for optimizing transfusion practices in this vulnerable population.
Purpose of the Study:
- To investigate the relationship between blood donor characteristics, RBC modifications and storage, and transfusion parameters with serious adverse outcomes in VLBW infants.
- To identify potentially modifiable factors in RBC transfusions that could improve VLBW infant outcomes.
Main Methods:
- A prospective birth cohort study involving VLBW infants (<1500 g) across multiple US hospitals.
- Data linkage of electronic medical records, blood donor information, and Vermont Oxford Network outcome data.
- Multivariable generalized estimating equation regression models were used to analyze associations between transfusion characteristics and a composite outcome of severe morbidities or mortality.
Main Results:
- Higher pretransfusion hemoglobin levels were associated with increased odds of the composite outcome (OR, 1.15 per 1 g/dL increase).
- Use of additive solutions (AS)-1 or AS-5 was linked to lower odds of the composite outcome compared to older solutions.
- Specific factors like transfusion dose, donor age, storage duration, and donor sex showed associations with individual secondary outcomes, including mortality, BPD, NEC, and IVH.
Conclusions:
- Pretransfusion hemoglobin and the type of anticoagulant preservative solution are key modifiable factors associated with composite morbidities and mortality in VLBW infants.
- While many modifiable blood banking practices did not show significant associations, specific donor and blood banking factors warrant further investigation as potential targets for improving VLBW infant care.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Rh Blood Group
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...